ImmunityBio (IBRX) Stock: Climbs as FDA Expands ANKTIVA Approval for Bladder Cancer
TLDR IBRX climbs 1.12% to $9.91 as FDA expands ANKTIVA’s bladder cancer approval. FDA clears ANKTIVA plus BCG for papillary-only…
Market coverage 1 stories
TLDR IBRX climbs 1.12% to $9.91 as FDA expands ANKTIVA’s bladder cancer approval. FDA clears ANKTIVA plus BCG for papillary-only…